Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

03. April 2013 17:30 ET | Quelle: Intellipharmaceutics International Inc.

Intellipharmaceutics Announces First Quarter 2013 Results

TORONTO, April 3, 2013 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I), a pharmaceutical company specializing in the research, development and manufacture of novel...
25. März 2013 14:52 ET | Quelle: Intellipharmaceutics International Inc.

Intellipharmaceutics Closes US$3.1 Million Registered Direct Offering of Units

TORONTO, March 25, 2013 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I), a pharmaceutical company specializing in the research, development and manufacture of novel...
19. März 2013 09:07 ET | Quelle: Intellipharmaceutics International Inc.

Intellipharmaceutics to Raise US$3.1 Million

TORONTO, March 19, 2013 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I), a pharmaceutical company specializing in the research, development and manufacture of novel...
13. März 2013 18:00 ET | Quelle: Intellipharmaceutics International Inc.

Intellipharmaceutics Announces Update on Its Generic Versions of Keppra XR(R) and Pristiq(R)

TORONTO, March 13, 2013 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I), a pharmaceutical company specializing in the research, development and manufacture of novel...
31. Januar 2013 21:52 ET | Quelle: Intellipharmaceutics International Inc.

Intellipharmaceutics Announces 2012 Year End Results

TORONTO, Jan. 31, 2013 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I), a pharmaceutical company specializing in the research, development and manufacture of novel...
10. Januar 2013 17:00 ET | Quelle: Intellipharmaceutics International Inc.

Intellipharmaceutics Closes US$1.5 Million Convertible Debenture Financing

TORONTO, Jan. 10, 2013 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I), a pharmaceutical company specializing in the research, development and manufacture of novel...
07. Januar 2013 08:00 ET | Quelle: Intellipharmaceutics International Inc.

Intellipharmaceutics Announces Proposed Convertible Debenture Financing

TORONTO, Jan. 7, 2013 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I), a pharmaceutical company specializing in the research, development and manufacture of novel and...
27. November 2012 07:00 ET | Quelle: Intellipharmaceutics International Inc.

Intellipharmaceutics Announces Results of Initial Phase I Clinical Trial of Controlled-Release Pregabalin and Product Updates

TORONTO, Nov. 27, 2012 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I), a pharmaceutical company specializing in the research, development and manufacture of novel...
21. November 2012 07:00 ET | Quelle: Intellipharmaceutics International Inc.

Intellipharmaceutics to Present at the 24th Annual Piper Jaffray Healthcare Conference

TORONTO, Nov. 21, 2012 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I), a pharmaceutical company specializing in the research, development and manufacture of novel...
02. Oktober 2012 17:00 ET | Quelle: Intellipharmaceutics International Inc.

Intellipharmaceutics Announces Third Quarter 2012 Results

TORONTO, Oct. 2, 2012 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I), a pharmaceutical company specializing in the research, development and manufacture of novel and...

Vorherige Seite

Nächste Seite